Skip to main content
editorial
. 2019 Jun 4;10(38):3579–3580. doi: 10.18632/oncotarget.26986

Figure 1. Mechanisms of obstruction of gemcitabine (GEM) delivery in pancreatic cancer.

Figure 1

(A) Cyr61/CCN1 overexpression results in GEM-inactivation in PDAC cells. Cyr61/CCN1 suppresses dCK expression, which is needed to activate GEM. (B) Tumor cell-secreted Cyr61/CCN1 promotes desmoplasia via enhancing CTGF/CCN2 levels in fibroblasts. T, primary tumors; α-SMA, alpha-smooth muscle.